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 Non-technical Summary 
Research and development (R&D) collaborations allow firms to combine their 
resources, exploit complementary know-how and internalize R&D externalities. 
Hence, R&D collaborations may spur innovation activities in the private sector. Firms 
can, however, be reluctant to engage in R&D collaboration if they fear unwanted 
knowledge spillovers to partners. Losing highly valuable knowledge to potential 
competitors through collaborations poses a direct threat of a firm’s market position. A 
means to control outgoing spillovers are formal intellectual property rights, such as 
patents. 
This paper focuses on the interplay between intellectual property rights and R&D 
collaboration. We investigate the impact of uncertain intellectual property rights on 
firms’ collaborative R&D activities. Our study is motivated by recent trends in the 
European patent system. While the patent examination process at the European Patent 
Office (EPO) takes relatively longer than at the United States Patent and Trade Mark 
Office, the duration of the patent examination at the EPO further increased 
significantly after a surge in patent applications in the mid 1990s. In response, firms 
face higher uncertainty about their certified intellectual property rights in Europe, in 
general, and especially since the 1990s.  
In this study, we argue that patent pendencies create uncertainty and shape the relative 
return of R&D collaboration agreements. We show that, depending on the type of 
partner, uncertain intellectual property rights reduce R&D collaboration which may 
hinder the production of knowledge in the economy. Empirical results from a sample 
of almost 3,000 firms engaged in product and/or process innovations in German 
manufacturing indicate that collaboration between competitors is most sensitive to 
uncertain intellectual property rights as compared to collaborations with universities, 
suppliers or customers.  
Our findings have important implications for technology policy. Governments have 
long understood the virtues of R&D collaboration by exempting R&D partnerships 
from anti-trust legislation and implementing several policies to encourage R&D 
collaborations. Our results show that a functional intellectual property rights system is 
needed for successful utilization of this policy: patent examination should be of high 
quality, but should also be performed in a timely manner. 
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Abstract 
Patent pendencies create uncertainty in research and development (R&D) 
collaboration agreements, resulting in a threat of expropriation of unprotected 
knowledge by potential partners, reduced bargaining power and enhanced search 
costs. In this paper, we show that - depending of the type of partner - uncertain 
intellectual property rights (IPR) lead to reduced collaboration between firms and may 
hinder the production of knowledge. This has implications for technology policy as 
R&D collaborations are exempt from anti-trust legislation in order to increase R&D in 
the economy. We argue that a functional IPR system is needed for successful 
utilization of this policy. 
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1 Introduction 
Confronted with intense technology competition and an increased complexity of 
technological inventions, successful creation of new knowledge often depends on the 
ability of firms to establish cooperative research and development (R&D) agreements 
in order to combine their resources, exploit complementary know-how and internalize 
R&D externalities (Katz, 1986; d’Aspremont and Jacquemin, 1988; Kamien et al., 
1992).  
R&D collaborations allow firms to internalize knowledge spillovers, thus eliminating 
the free rider problem in the market for ideas and to benefit from economies of scale 
and scope. Often only a consortium of firms has the necessary resources both 
financially and physically to undertake the ever larger, more complex, and more 
expensive research projects. Synergetic effects and risk pooling may also broaden the 
research horizon of cooperating firms. Hence, it can be expected that sustaining R&D 
cooperatives leads to an increase in private R&D activity (see Veugelers, 1998, for a 
survey of theoretical and empirical literature). 
Unwanted knowledge spillovers to collaboration partners that go beyond the 
contracted research project are clear drawbacks of engaging in R&D collaborations. 
Losing highly valuable knowledge to potential competitors through direct 
collaborations or collaboration agreements with common customers or suppliers 
places a direct threat of a firm’s market position. In order to control outgoing 
spillovers through collaboration, firms seek formal intellectual property protection 
before engaging in partnerships (Brouwer and Kleinknecht, 1999). 
This paper focuses on the interplay between intellectual property rights and R&D 
collaboration. In particular, we investigate the impact of uncertain intellectual 
property rights on firms’ collaborative R&D activities. Our study is motivated by 
recent trends in the European patent system. While the patent examination process at 
the European Patent Office (EPO) takes relatively longer than at the United States 
Patent and Trade Mark Office (Popp et al., 2004, Harhoff and Wagner, 2009) the 
duration of patent examination at the EPO further increased significantly after a surge 
in patent applications in the mid 1990s (OECD, 2008) due to an insufficient 
expansion of the workforce at the EPO (Harhoff and Wagner, 2009). Thus, firms face 
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higher uncertainty about their certified intellectual property rights in Europe, in 
general, and especially since the 1990s.  
In this paper, we argue that patent pendencies create uncertainty and shape the relative 
returns of R&D collaboration agreements. High levels of uncertainty in R&D 
partnerships result in a threat of expropriation of unprotected knowledge by potential 
partners, reduced bargaining power, enhanced search costs and asymmetric 
information. We show that, depending on the type of partner, uncertain intellectual 
property rights reduce R&D collaboration which may hinder the production of 
knowledge in the economy.  
We argue that collaboration between competitors is more sensitive to uncertain 
intellectual property rights than collaborations between a firm and universities, 
suppliers or customers. Empirical evidence from a sample of almost 3,000 firms 
engaged in product and/or process innovations in German manufacturing confirm our 
hypotheses: firms are less likely to engage in R&D collaboration with competitors in 
response to uncertain patents, while collaborations with universities, customers and 
suppliers are unaffected.  
This has important implications for technology policy. Governments have long 
understood the virtues of R&D collaboration and have exempted R&D partnerships 
from anti-trust legislation. In the European Union, for instance, the Treaty of Rome 
already contained a notice in article 85(3) that collaborating in R&D is permitted as 
long as post-innovation competition is not hampered. In 1984, the European 
Commission approved a block exemption for R&D collaborations that also allows 
joint exploitation of results (see Martin, 1997 for an overview on policy practices in 
the U.S., Japan and Europe). Our results show that a functional intellectual property 
rights (IPR) system is needed for successful utilization of this policy: patent 
examination should be of high quality, but should also be performed in a timely 
manner.  
The remainder of this paper is organized as follows. Section 2 describes the 
conceptual background of patent pendencies and their involved legal uncertainty as 
well as the implications for R&D collaboration in more detail. The third section 
introduces the data and variables for our empirical test, and the fourth section presents 
the econometric results. Section 5 concludes. 
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2 Background 
The theoretical and empirical literature on R&D collaboration emphasizes the 
importance of incoming spillovers, appropriability and absorptive capacity for the 
decision to enter collaborative R&D agreements (d’Aspremont and Jacquemin, 1988; 
Kamien and Zang, 2000; Cassiman and Veugelers, 2002). Firms aim at maximizing 
the inflow of information from collaboration partners and other market participants 
(incoming spillovers) while trying to minimize the outflow of information 
(appropriability). To manage incoming information flows, firms invest in “absorptive 
capacity” defined as the ability to recognize, assimilate and utilize external knowledge 
(Cohen and Levinthal, 1989). To control leakage of valuable intellectual assets, 
however, firms aim at protecting their proprietary knowledge through formal means 
such as patents. 
Our empirical model builds on this stream of research by analyzing the occurrence of 
R&D collaboration with uncertain IPRs. Formal IPRs reduce the threat of 
expropriation between partners but also transaction costs of bargaining. Because of 
the threat of expropriation, innovators with pending patents (applications that are still 
under review at the patent office) might be reluctant to enter cooperative agreements. 
At the same time, pending patents reduce the bargaining power of a firm when 
contracting over R&D outside its boundaries and enhances its search costs. 
We first discuss the types of uncertainty generated by the patent system and then 
detail their implications for collaborative R&D. 
2.1 Patent pendencies and uncertainty 
Patent pendencies create legal and economic uncertainty. Gans et al. (2008) review 
the distinct types of uncertainty over patent rights.  
1. Patent grant uncertainty: the first source of uncertainty arises from the outcome 
of the application procedure. Uncertainty over patent rights is resolved once a 
final decision on the status of the application is reached. A patent can be 
formally awarded by the patent office (PTO), but applications can also be 
refused a grant by the examiner or can be terminated by the applicant. Harhoff 
and Wagner (2009) show that about 2/3 of all applications are eventually 
approved at the EPO. Innovators may therefore be reluctant to enter 
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collaborative agreements and disclose unprotected information before the 
patenting process is completed. 
2. Patent scope uncertainty: Examiners may require the applicant to change the 
specification of the patent and narrow the scope of the claimed invention in the 
course of the examination procedure. If the examiner and the applicant find an 
agreement, the patent might be awarded to the applicant. If no such agreement is 
found, the application may be withdrawn by the applicant or refused a grant by 
the PTO. Until a final decision is taken by either party, considerable uncertainty 
exists over the scope of the (potential) patent award.  
3. Pendency uncertainty: The duration of patent examination varies substantially 
across technological areas, patent and applicants characteristics (Harhoff and 
Wagner, 2006; Popp et al., 2004; Regibeau and Rockett, 2007). Innovators may 
face substantial opportunity costs if they delay commercialization, new projects 
or cooperative agreements as a consequence of patent pendencies. 
4. Economic and strategic uncertainty: In addition to the legal uncertainty, there is 
substantial uncertainty associated with the economic and strategic value of the 
invention. The value of (patented) inventions is highly skewed with most patents 
having no or little economic value (Harhoff et al., 1999). The value of the 
underlying invention may only become apparent to the applicant, to competitors 
and potential partners and licensees once the uncertainty of patent rights is 
resolved.   
In the next subsection, we explore the implication of these uncertainties on the 
occurrence of R&D collaboration. 
2.2 Implications of uncertain IPRs on R&D collaboration. 
The theoretical literature emphasizes that R&D partners attempt to manage spillovers, 
trying to minimize knowledge leakages (Cassiman et al., 2002; Martin, 2002; Amir et 
al., 2003). In addition, imperfect appropriability may increase the incentives of firms 
to free-ride on each other’s R&D investment (Shapiro and Willig, 1990; Kesteloot and 
Veugelers, 1995; Eaton and Eswaran, 1997). The empirical literature confirms the 
critical importance of appropriability for successful collaboration (Cassiman and 
Veugelers, 2002; Gans et al., 2002). 
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We argue that uncertain IPRs exacerbate these effects for several reasons. First, an 
innovator with patent applications under review at the PTO is under the threat of 
expropriation. Even though patent applications are usually made publicly available 
when the formal examination starts, an applicant is likely to have detailed information 
beyond the mere technical description of the claimed invention (Teece, 1981; Arora, 
1995). Therefore patent pendencies may have an impact on the risk of expropriation 
and on the willingness of the applicant to disclose unprotected information. 
Appropriation concerns are prevalent in horizontal cooperative agreements (with 
competitors). Minimizing opportunistic partner behavior in cooperative contracts will 
be more pronounced when the existing research portfolio of a firm is characterized by 
a large amount of uncertainty. By contrast, the threat of expropriation is lower in 
vertical cooperation (with customers or suppliers) that is directed at cost reduction or 
customer acceptance of new products, or institutional collaboration (with universities) 
that covers more generic knowledge production (Belderbos et al. 2004).  
Second, uncertain property rights decrease the bargaining power of firms seeking to 
collaborate. The literature suggests that the rational for collaboration is to combine the 
firms’ existing resources to exploit complementarities (Kogut, 1998; Roeller et al., 
2007). Because formal IPRs such as patents can serve as a vehicle for the 
formalisation of technology exchange arrangements between partners (Brouwer and 
Kleinknecht, 1999) and as a bargaining chip in negotiation with potential partners 
(Blind et al., 2006), firms with uncertain patents may be at a comparative 
disadvantage when negotiating the terms of the agreement and the division of rents. 
Third, uncertain patents increase search costs. The greater a firm's stock of resources, 
the greater the firm's attractiveness to partners, and the greater the firm's collaboration 
opportunities (Ahuja, 2000). Therefore, the incentives to engage in costly search for 
partners may only be sufficient once the uncertainty over IPRs is resolved (Gans et al. 
2008; Hellmann, 2007).  
3 Data and Variables 
3.1 Firm level and patent data  
The main data source is the Mannheim Innovation Panel (MIP), a survey that has been 
conducted annually by the Centre for European Economic Research (ZEW) on behalf 
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of the German Federal Ministry of Education and Research (BMBF) since 1992. The 
MIP is the German part of the Community Innovation Survey (CIS) of the European 
Commission.  
In 1992 and 1996 firms reported their involvement in collaborative R&D.2
The questionnaire asked respondents to distinguish between different types of 
collaboration: horizontal collaboration (with competitors), institutional collaboration 
(with universities and public research institutions) and vertical collaboration (with 
suppliers and customers). In addition, the MIP provides comprehensive information 
on the firms’ innovation activities. The MIP survey years 1992 and 1996 constitute a 
pooled cross-sectional database for our empirical analysis.
 Innovation 
collaborations are defined as “active participation in joint innovation projects with 
other organizations. These may either be other enterprises or non-commercial 
institutions. The partners need not derive immediate benefit from the venture. Pure 
contracting out of work, where there is no active collaboration, is not regarded as co-
operation. Co-operation is distinct from open information sources and acquisition of 
knowledge and technology in that all parties take an active part in the work” (OECD, 
2005). 
3
Table 1 shows descriptive statistics for the variables used for the empirical analysis. It 
shows that about a quarter of the innovative firms in German manufacturing are 
involved in some kind of R&D collaboration. About 17% of the firms collaborated 
with universities, 18% with suppliers or customers (vertical collaboration) and a much 
smaller share of 6% collaborated with competitors. 
 We restrict the sample to 
manufacturing firms only and exclude firms that were not engaged in process and/or 
product innovations. This leaves us with a total of 2,795 sample firms. 
Information on the patenting activity of firms is taken from the patent database of the 
EPO. Firm and patent information were linked based on firms’ names and addresses. 
The match between firms and their EPO patent applications was conducted using a 
                                                 
2 This question was also part of the MIP survey in 2000 and 2004. However, we abstain from using this 
more recent data because the information on pending patents is added from EPO data and we want to 
avoid that our results are driven by reporting lags of the outcome of patent decisions, i.e. right-
censoring of the patent data (see e.g. Harhoff and Wagner, 2009). 
3 Only 15.5% of the firms in our sample of innovative firms in German manufacturing responded to the 
survey in both years. 
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computer-assisted text-based search algorithm. All potential hits were checked 
manually. In total, 27% of the sample firms applied for at least one patent at EPO 
since its inception in 1978.  
3.2 Pending Patents at the EPO 
The number of pending patents at the EPO has risen sharply over time. Figure 1 
shows the evolution of the number of applications and the number of pending 
applications at the EPO. The surge in patenting observed at the EPO lead to a backlog 
of pending cases, amounting to more than 500,000 in the beginning of the year 2001. 
Figure 1: Applications and pendencies at the EPO 
 
Source: Espace Bulletin (EPO). Authors’ own calculations. 
 
Harhoff and Wagner (2009) report that in the period 1978-2000, it took on average 
4.3 years from the initial filling to the grant decision. Popp et al. (2004) show that in 
the period 1976-1996, the average grant lag for utility patents awarded by the United 
States Patent and Trademark Office (USPTO) was about 2.3 years. It appears that the 
average grant lag at the EPO is longer than at the USPTO and that this gap has been 
increasing significantly over time (Harhoff and Wagner, 2009). This difference can be 
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explained by the divergent practices adopted by both patent offices in the wake of 
increasing inflows of applications. The USPTO granted patents of dubious merit in 
order to deliver patent awards in a timely manner (Lemley, 2001), whereas the EPO 
attempted to maintain high quality in examination, creating enormous backlogs of 
applications (Guellec and van Pottelsberghe de la Potterie, 2007, Harhoff and 
Wagner, 2009).  
We make use of the EPO information to define our measure of uncertain IPRs as the 
number of pending patent applications. Pending applications are defined as filings that 
are still under review at the EPO in the year of interest.4
3.3 Control variables 
 Table 1 shows that the 
average firm in our sample has more than two pending patent applications at the EPO. 
The ratio of pending applications over the total application stock is 0.15. The latter 
measure is used in the empirical analysis to account for the fact that the patent stock 
and the number of pending patents are highly correlated. 
In addition to our main variable of interest, we use a rich set of control variables that 
were identified as determinants of R&D collaboration in the previous literature. We 
include proxy variables for appropriability, incoming R&D spillovers, absorptive 
capacity as well as indicators for the cost and risk of innovation, following the 
definitions proposed by Cassiman and Veugelers (2002).  
Appropriability describes the ability of firms to appropriate the returns from their 
innovations. Our measures for appropriability capture the effectiveness of different 
protection mechanisms. Following Cassiman and Veugelers (2002), we distinguish 
between legal and strategic protection tools. The legal protection measure maps the 
extent to which patents, trademarks and copyrights are effective for the protection of 
product and process inventions. Strategic protection is measured by the effectiveness 
of secrecy, complexity and lead time for the protection of product and process 
inventions. In the survey, respondents were asked to rate the effectiveness of the 
particular protection mechanisms on a Likert scale from one (unimportant) to five 
(highly important). The questions about the effectiveness of different protection tools 
                                                 
4 The patent application and review procedure at EPO involves several steps, which are briefly 
described in Appendix 1. 
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is only included in the 1992 survey wave. Therefore, we use the industry average of 
both strategic and legal protection (rescaled between 0 and 1) in 1992 at the 3-digit 
NACE level for both waves. 
Furthermore, we control for incoming spillovers. Again, we use particular questions 
from the MIP survey, namely the questions on the importance of different sources of 
information for firms’ innovation activities. In line with Cassiman and Veugelers 
(2002), we focus on public spillovers which include the importance of patent 
information, specialized conferences, meetings and publications as wells as trade 
shows and seminars. For these questions too, firms were asked to rank the different 
information sources on a scale from unimportant to highly important. As for the 
appropriability measure, we rescale the variable between 0 and 1 and use the industry 
average at the 3-digit NACE level. 
The theoretical literature underscores the importance of cost and risk constraints as 
motives to establish R&D collaboration agreements (Katz, 1986, d’Aspremont and 
Jacquemin, 1988, Kamien et al., 1992). The previous empirical literature has found 
some evidence for the cost-sharing motive behind R&D collaborations (Cassiman and 
Veugelers, 2002, Schmidt, 2005, Roeller et al., 2007), while there is typically no 
effect for the risk-sharing motive (Cassiman and Veugelers, 2002; Schmidt, 2005). 
The survey allows us to proxy both the cost and risk constraints. Both survey years 
contain information about different obstacles to innovation, among them the costs of 
innovating and the risks and uncertainties of the innovation process. Firms for which 
the costs and risks of innovating are perceived to be high are more likely to be 
involved in R&D collaborations. Again, the obstacles were ranked on a scale between 
unimportant and highly important. We defined two binary variables, COST and RISK, 
which take the value one if costs or risks respectively were indicated as very 
important obstacles to innovation and zero otherwise. 
In addition, we use a range of further firm characteristics as control variables. First, 
we use firm size and R&D intensity. Larger and more R&D intensive firms are more 
likely to possess the necessary absorptive capacity to benefit from R&D cooperation 
and are therefore expected to have a positive impact on the likelihood to observe such 
agreements. Firm size is measured as the total number of employees, EMPL. We use 
the logarithm of this number to account for the skewness of the distribution. R&D 
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intensity is measured as R&D expenses over total sales. Table 1 shows that the 
average firm in our sample has 691 employees and an R&D intensity of 2%. 
The patent application stock accounts for the importance of the ownership of IP for 
collaboration. The patent applications stock is measured as:  
,  
where δ represents the constant knowledge depreciation rate, which is set to 15 
percent as it is standard in the literature (e.g. Griliches and Mairesse, 1984, or Hall, 
1990). The patent stock enters our specification with a one year lag to avoid 
endogeneity. In order to avoid collinearity with firm size, we divide the patent stock 
by employment. On average, the firms in our sample have a patent stock over 
employment of 0.004. As the sample includes a large fraction of firms that never 
applied for a patent we also include a binary variable that takes on the value one for 
firms with no patent application and zero otherwise. 
In addition, we control for industry affiliation using eleven industry dummies and a 
dummy for complex technology industries. Complex technology industries capture 
sectors characterized by technologies that enclose a large number of complementary 
patentable elements. Firms operating in complex industries face a higher density of 
patent applications, which decreases transparency in technology markets and therefore 
increases the threat of patent thickets and blocking patents (Cohen et al., 2000). It has 
been shown that technology licensing is one method to overcome hold-up problems in 
complex industries (Siebert and von Graeventiz, 2010, Grimpe and Hussinger, 2009). 
R&D collaboration may constitute an alternative solution. 
By including a dummy, EAST, for firms located in the Eastern part of the country, we 
take the turbulent past of Germany into account. East Germany was a planned 
economy until the fall of the Berlin wall in 1989. Since then, East Germany has been 
undergoing a transition process into a market economy. Recent studies have shown 
that East German firms still lag behind their West German counterparts in terms of 
innovativeness (Czarnitzki and Kraft, 2006) and productivity (Czarnitzki, 2005). 
Finally, we include the Hirschman-Herfindahl index (HHI) to control for product 
market competition. We also use a dummy indicating firms that were founded in the 
recent two years, as start-up companies may be more like to rely on collaboration than 
other firms. In contrast, it may also be the case that they are not collaborating as they 
ttt nsapplicatiopatentPSPS   )1(1 +−= − δ
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may not be attractive partners for more established companies. Last but not least, we 
include a time dummy, Y1992, to capture macroeconomic shocks across the two time 
periods. 
Table 1: Descriptive statistics (2,794 observations) 
Variable Mean Std. dev. Min. Max. 
Collaboration 0.24 0.43 0 1 
… with competitors 0.06 0.24 0 1 
… with universities 0.17 0.37 0 1 
… vertical 0.18 0.38 0 1 
R&D (in million DM) 7.50 83.30 0 2302 
R&D/sales 0.02 0.05 0 0.57 
Patent stock 2.90 55.37 0 2866.50 
Patent stock / EMPL 0.004 0.01 0 0.27 
No patents 0.73 0.45 0 1 
Complex industry 0.43 0.50 0 1 
Pending patents 2.29 42.01 0 2121 
Pending patents/ patent stock 0.15 0.36 0 2.25 
EMPL 691.31 5279.51 1 177183 
Newly founded 0.18 0.39 0 1 
HHI 44.73 64.30 3.32 444.95 
EAST 0.31 0.46 0 1 
COST 0.40 0.49 0 1 
RISK 0.43 0.49 0 1 
Incoming spillovers 0.64 0.07 0.44 0.79 
Strategic appropriability 0.71 0.05 0.60 0.80 
Legal appropriability 0.49 0.07 0.29 0.67 
Y1992 0.58 0.49 0 1 
Note: Industry dummies omitted. 
4 Empirical Results 
In a first step, we investigate the effects of pending patent applications on all forms of 
collaboration. Then, we distinguish between different types of collaboration, i.e. 
horizontal collaborations, institutional collaborations and vertical collaborations. We 
present probit models for each type of collaboration and for two different 
specifications. The first specification includes a set of standard control variables along 
with the pending applications over the patent application stock. The control variables 
are R&D intensity, the patent application stock per employee, the binary variable 
indicating whether a firm never applied for a patent, the log of firm size, the dummy 
for complex industries and the other industry dummies as well as the dummy for firm 
location in Eastern Germany and the time dummy. The second specification adds the 
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survey proxies for spillovers, the effectiveness of legal and strategic knowledge 
protection and the two dummy variables for cost and risk constraints. Further, the 
dummy for newly founded firms and the logarithm of the Hirschman-Herfindahl 
Index are included.  
In addition to the standard probit models, we report results where we instrument R&D 
intensity by estimating Full Information Maximum Likelihood Probit instrumental 
variable models. R&D intensity is a potential source of endogeneity in our model, as 
the firms’ collaboration activities and their R&D intensity are likely to depend on 
some unobservable firm-specific factors like, for instance, the managerial skills that 
are used to optimize firms’ innovation activities. We use the share of R&D 
employment at the 3-digit NACE level as an instrument for R&D intensity. The 
industry variable defines the R&D environment in which the firms operate and the 
key assumption behind industry level instruments is that the unobserved firm 
characteristics do not significantly affect the industry variables (Jaffe, 1986).  
Endogeneity of R&D intensity with regard to all collaboration variables cannot be 
rejected based on Rivers and Vuong (1988) tests. This test requires a first step 
regression of R&D intensity on all regressors and the instrument. The predicted 
residuals of this model are included in a second regression of the collaboration 
variables on all regressors. The estimated coefficient for the residual is the test 
statistic for the null hypothesis of exogeneity of R&D intensity (Wooldridge, 2002, 
p.474). Exogeneity is rejected at the 1% level of statistical significance for all our 
models.  
Stock and Staiger (1997) emphasize that endogeneity tests can be misleading in case 
of weak instruments. If instruments are weak the correlation between the endogenous 
variable and the instrument can be artificially high due to the presence of other control 
variables. Staiger and Stock (1997) propose evaluating the partial correlation of the 
endogenous variable and the instruments as a test for weak instruments. As a rule of 
thumb, the partial F-statistic for the instrument(s) should be larger than 10 to ensure 
that instruments are not weak. The F-statistic exceeds 10 for both specifications (F = 
44.99 for the full specification; F = 49.13 for the baseline specification).  
Tables 2 to 5 show the results for all types of collaboration, horizontal collaboration, 
institutional collaboration, and vertical collaborations. The first two columns show the 
results of the probit models for the baseline and full specifications. The next two 
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columns show the results of the instrumental variable probit regressions for both 
specifications. 
The regression results reveal that there is no impact of uncertain IPRs on collaboration 
in general (Table 2). Tables 3 to 5 show that pending patents are only significant for 
R&D collaborations with competitors. Uncertain IPRs decrease the likelihood of 
collaborating with competitors, while there is no effect of this variable on the 
likelihood of collaborating with scientific institutions or suppliers and customers. 
With regard to the marginal effect of pending patents we find a non-negligible 
magnitude. Among firms with patent applications the average probability to 
collaborate with a competitor amounts to 13%. The probability of collaborating with a 
competitor decreases by 3% points for these firms if the share of pending patents in 
the patent application stock increases by one standard deviation at the mean. Thus, the 
average probability of collaborating with firms in the same industry is reduced by 
about 23% (=3/13), which is a sizeable impact.  
Concerning the control variables the estimation results reveal some significant 
predictors for R&D collaboration. As expected, large firms and firms with a high 
R&D intensity are more likely to collaborate with all types of partners. In line with 
the concept of absorptive capacity, firms need a sufficient level of in-house R&D in 
order to benefit from collaborations (Roeller et al., 2007, Cassiman and Veugelers, 
2002).5
Focusing on the survey proxies suggested by Cassiman and Veugelers (2002) the 
regression results show that cost and risk sharing drive R&D collaborations. The 
effect of innovation costs however disappears if it is distinguished between the 
different types of collaboration. The risk sharing motive is strongest for vertical 
 Interestingly, the size of the patent application stock is not important for the 
collaboration decision. The patent stock is only significant for university 
collaborations and there is weak evidence for their importance for vertical 
collaboration agreements. A further interesting result is that vertical collaborations are 
in particular attractive in industries employing complex technologies. The further 
control variables do not exhibit any significant impact on the likelihood of R&D 
collaborations. 
                                                 
5 However, the effect of R&D intensity disappears for collaborations with scientific institutions and 
vertical collaborations if endogeneity of R&D intensity is taken into account. 
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collaborations. This finding stands in contrast to the results of Cassiman and 
Veugelers (2002) and Schmidt (2005) who find evidence for the importance of cost 
sharing but not of risk-sharing. A potential explanation can be the difference in the 
definition of these variables. While Cassiman and Veugelers (2002) and Schmidt 
(2005) use a Likert scale variable describing the importance of costs and risks as 
obstacles for innovation we can only use a dummy variable for our sample. 
We do not find any effect of the industry measures for appropriability and incoming 
spillovers either.  
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Table 2: Probit models on the likelihood to collaborate with any type of partner 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 4.00*** 3.73*** 10.23*** 9.53** 
 (0.70) (0.70) (3.62) (3.97) 
Patent stock / EMPL 2.73 2.67 1.66 1.64 
 (2.03) (2.07) (2.15) (2.20) 
No patent dummy -0.10 -0.12 -0.08 -0.07 
 (0.09) (0.10) (0.09) (0.10) 
Complex technology 0.58*** 0.51** 0.43** 0.39* 
 (0.18) (0.21) (0.20) (0.22) 
Pending pat./pat. stock 0.08 0.08 0.02 0.03 
 (0.10) (0.10) (0.11) (0.11) 
Ln(EMPL) 0.33*** 0.34*** 0.31*** 0.32*** 
 (0.02) (0.02) (0.03) (0.03) 
Newly founded  -0.04  -0.04 
  (0.10)  (0.10) 
Ln(HHI)  0.02  0.02 
  (0.03)  (0.03) 
EAST  0.17*  0.07 
  (0.09)  (0.11) 
COST  0.16**  0.14* 
  (0.08)  (0.08) 
RISK  0.23***  0.20** 
  (0.08)  (0.09) 
Incoming spillovers  -0.08  -0.17 
  (0.99)  (0.95) 
Strategic appropriability  0.38  0.16 
  (1.04)  (1.02) 
Legal appropriability  0.46  0.40 
  (0.70)  (0.69) 
1992 0.23*** 0.07 0.18** 0.05 
 (0.06) (0.11) (0.07) (0.11) 
Intercept -2.84*** -3.48*** -2.72*** -3.12*** 
 (0.23) (0.78) (0.26) (0.84) 
Industry dummies Χ2 = 40.65*** Χ2 = 30.16*** Χ2 = 29.65*** Χ2 = 23.11*** 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Table 3: Probit models on collaboration with competitors 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 2.46*** 2.48*** 12.18*** 11.68*** 
 (0.61) (0.62) (3.67) (4.04) 
Patent stock / EMPL -0.75 -1.12 -2.20 -2.45 
 (3.52) (3.68) (3.24) (3.42) 
No patent dummy -0.44*** -0.41*** -0.36*** -0.31** 
 (0.12) (0.13) (0.12) (0.13) 
Complex technology 0.80** 0.67* 0.52 0.46 
 (0.33) (0.35) (0.33) (0.35) 
Pending pat./ pat. stock -0.31** -0.30** -0.36*** -0.34*** 
 (0.13) (0.13) (0.12) (0.12) 
Ln(EMPL) 0.25*** 0.24*** 0.21*** 0.20*** 
 (0.03) (0.03) (0.04) (0.04) 
Newly founded  0.15  0.14 
  (0.15)  (0.14) 
Ln(HHI)  0.06  0.06 
  (0.04)  (0.04) 
EAST  -0.16  -0.28** 
  (0.15)  (0.14) 
COST  0.06  0.03 
  (0.12)  (0.11) 
RISK  0.25*  0.18 
  (0.13)  (0.12) 
Incoming spillovers  -0.38  -0.62 
  (1.38)  (1.24) 
Strategic appropriability  0.48  0.14 
  (1.63)  (1.49) 
Legal appropriability  1.21  0.92 
  (0.95)  (0.89) 
1992 -0.16* -0.29* -0.20*** -0.27* 
 (0.08) (0.15) (0.08) (0.14) 
Intercept -3.11*** -3.97*** -2.75*** -3.12** 
 (0.37) (1.27) (0.43) (1.26) 
Industry dummies 
Χ2 = 
36.71*** Χ2 = 21.01** Χ2 = 13.80 Χ2 = 10.96 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Table 4: Probit models on collaboration with universities 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 3.83*** 3.73*** 8.12* 7.13 
 (0.65) (0.66) (4.28) (4.57) 
Patent stock / EMPL 5.14** 5.07** 4.38* 4.47* 
 (2.09) (2.11) (2.27) (2.30) 
No patent dummy -0.12 -0.12 -0.11 -0.09 
 (0.10) (0.10) (0.10) (0.11) 
Complex technology 0.40* 0.35 0.31 0.29 
 (0.20) (0.23) (0.23) (0.25) 
Pending pat. / pat. stock 0.07 0.07 0.03 0.04 
 (0.11) (0.11) (0.11) (0.11) 
Ln(EMPL) 0.34*** 0.33*** 0.33*** 0.33*** 
 (0.02) (0.02) (0.03) (0.03) 
Newly founded  -0.06  -0.05 
  (0.11)  (0.11) 
Ln(HHI)  0.03  0.04 
  (0.03)  (0.03) 
EAST  0.06  0.01 
  (0.10)  (0.12) 
COST  0.03  0.03 
  (0.09)  (0.09) 
RISK  0.16*  0.14 
  (0.09)  (0.10) 
Incoming spillovers  0.29  0.21 
  (1.12)  (1.11) 
Strategic appropriability  1.40  1.27 
  (1.17)  (1.18) 
Legal appropriability  0.21  0.17 
  (0.79)  (0.78) 
1992 0.21*** 0.11 0.18** 0.11 
 (0.07) (0.12) (0.08) (0.12) 
Intercept -3.17*** -4.58*** -3.11*** -4.37*** 
 (0.26) (0.91) (0.28) (0.96) 
Industry dummies Χ2 = 44.42*** Χ2 = 37.75*** Χ2 = 30.88*** Χ2 = 29.70*** 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Table 5: Probit models on vertical collaboration (customers and suppliers) 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 2.78*** 2.60*** 0.94 0.13 
 (0.63) (0.64) (4.40) (4.66) 
Patent stock / EMPL 3.46 3.49 3.72* 3.85* 
 (2.12) (2.15) (2.19) (2.23) 
No patent dummy -0.15 -0.15 -0.16 -0.16 
 (0.10) (0.10) (0.10) (0.10) 
Complex technology 0.68*** 0.67*** 0.71*** 0.71*** 
 (0.19) (0.21) (0.20) (0.22) 
Pending pat. / pat. stock 0.02 0.02 0.03 0.03 
 (0.10) (0.10) (0.11) (0.11) 
Ln(EMPL) 0.26*** 0.27*** 0.26*** 0.27*** 
 (0.02) (0.02) (0.02) (0.02) 
Newly founded  -0.04  -0.04 
  (0.11)  (0.11) 
Ln(HHI)  0.02  0.01 
  (0.03)  (0.03) 
EAST  0.08  0.11 
  (0.10)  (0.12) 
COST  0.14  0.14* 
  (0.08)  (0.08) 
RISK  0.28***  0.29*** 
  (0.09)  (0.09) 
Incoming spillovers  0.34  0.39 
  (1.05)  (1.05) 
Strategic appropriability  0.68  0.75 
  (1.11)  (1.12) 
Legal appropriability  -0.69  -0.67 
  (0.75)  (0.74) 
1992 0.14** -0.08 0.15** -0.07 
 (0.06) (0.12) (0.07) (0.12) 
Intercept -2.71*** -3.25*** -2.70*** -3.33*** 
 (0.24) (0.85) (0.24) (0.85) 
Industry dummies Χ2 = 32.14*** Χ2 = 29.67*** Χ2 = 32.46*** Χ2 = 30.82*** 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
 
Robustness checks 
We show some robustness checks in Appendix 2 and Appendix 3. Table 6 in 
Appendix 2 presents results of multivariate probit models which take the correlation 
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of the error terms of the collaboration equations into account. There is evidence for 
positive error term correlation. The results remain robust to the findings presented in 
Tables 3 to 5. Pending patents only affect collaborations with competitors. 
Some readers may be concerned about a potential omitted variable bias. It may be the 
case that the collaboration decision is partly driven by the “technological position” of 
a firm. On the one hand, a firm possessing the leading technological portfolio in its 
market may not be interested in collaboration. In particular, it may not be willing to 
collaborate with rivals. On the other hand, firms holding key patents might be more 
likely to collaborate because they have more to offer to potential partners. We model 
the technological position of a firm by adding a quality indicator of a firm’s patent 
stock. Therefore, we compute the stock of forward patent citations, i.e. all citations 
received in future patent applications. Patent forward citations are a well established 
measure for the “importance”, the “quality” or the “significance” of a patented 
invention and have been used in different contexts in the literature on technological 
change (see Trajtenberg, 1990; Henderson et al., 1998; Harhoff et al., 1999; 
Trajtenberg, 2001; or Hall et al., 2005). 
In order to avoid a right-hand censoring of the citation variables, we limit the citation 
time window to five years after the patent application. The variable enters the 
regression as all forward citations received divided by the number of total patent 
applications. On average, a patent receives 0.16 citations in the future five years in our 
sample (std. dev. = 0.5). In addition to the citations over patent applications we 
include a dummy variable indicating if a firm did not receive any citation within the 
five-year window. 33% of the patenting firms (and 82% of the firms in total) received 
no citations to their patents within five years after application. 
Tables 7 to 10 in Appendix 3 show that the results are robust with regard to all earlier 
results. Pending patents only impact the likelihood to collaborate with competitors 
while they do not matter for other types of collaboration. There is no robust finding 
for the quality of patents influencing the likelihood to collaborate with any type of 
partner.6
                                                 
6 We also tested whether there is a nonlinear relationship between the citation variable and the 
likelihood of collaboration but did not find significant effects. 
 If at all, we find weak indications that the quality of the technological 
portfolio increases the likelihood to collaborate. 
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5 Conclusion 
Against the background of an increased duration of the patent examination procedure 
at the European Patent Office (EPO) this paper investigates whether the so created 
uncertainty impacts firms’ R&D collaborations. After a surge in patent applications in 
the mid 1990s the EPO suffered from a lack of qualified examiners. Rather than 
cutting back on patent quality the time for patent investigation at the EPO increased. 
The consequence is that firms face higher uncertainty about their certified intellectual 
property rights which might have important implications for their R&D activities. 
Intellectual property rights are highly important for firms that engage in R&D 
collaborations in order to limit the threat of expropriation of unprotected knowledge 
by potential partners. Furthermore, uncertain intellectual property rights reduce the 
bargaining power of collaboration partners and enhance search costs and asymmetric 
information for potential collaborators. In this study, we show that uncertain 
intellectual property rights lead to less collaboration among firms in the same 
industry, which implies less knowledge production in the economy because complex 
R&D projects that demand a bundle of resources and different skills in order to be 
realized may not be conducted. In particular, our empirical results for a large sample 
of German manufacturing firms reveal that collaborations between competitors are 
most sensitive to uncertain intellectual property rights. Firm collaborations with 
universities, suppliers or customers are not affected by uncertain intellectual property 
rights because these collaboration partners do not compete in the same product 
markets.  
Our findings have important implications for technology policy. Governments have 
long understood the virtues of R&D collaboration by exempting R&D partnerships 
from anti-trust legislation and implementing several policies to encourage R&D 
collaborations. Our results show that a functional intellectual property rights system is 
needed for successful utilization of this policy: patent examination should be of high 
quality, but should also be performed in a timely manner. 
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Appendix 1: Application procedure at the EPO 
 
A brief sketch of the steps from application to grant/refusal decision is given below:7
- After an application was filed, patent examiners prepare a search report 
describing the state of the art regarded as relevant for the patentability of the 
invention.
 
8
- Eighteen months after the priority date of the patent application the patent 
application is made public along with the search report in the EPO Patent 
Bulletin.  
  
- Within six months after publication, applicants can request for substantial 
examination of the application. If examination is not requested, the patent is 
deemed withdrawn.  
- If examination is requested a decision on the patentability of the invention is 
made according to the EPO patentability criteria: novelty, inventive step and 
industrial applicability. The examination can end by a grant or refusal to grant. 
- The applicant can voluntarily withdraw the application at each step of the 
procedure. 
                                                 
7 A more detailed description can for example been found in Harhoff and Wagner (2009). 
8 Note that unlike in the U.S. patent applicants at the EPO are not required to supply a list of prior art 
themselves. 
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Appendix 2: Multivariate Probit Models  
Table 6: Multivariate probit models for different types of collaboration 
 Model I Model II 
Collaboration type 
Equation 1: 
competitor 
Equation 2: 
university 
Equation 3: 
vertical 
Equation 1: 
competitor 
Equation 2: 
university 
Equation 3: 
vertical 
 Coeff. Coeff. Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 2.82*** 3.76*** 2.79*** 2.77*** 3.61*** 2.56*** 
 (0.70) (0.57) (0.57) (0.73) (0.58) (0.58) 
Patent stock / EMPL -1.12 4.90** 3.44 -1.65 4.87** 3.48 
 (3.08) (2.31) (2.16) (3.12) (2.33) (2.20) 
No patent dummy -0.42*** -0.12 -0.15 -0.40*** -0.11 -0.15 
 (0.12) (0.10) (0.10) (0.13) (0.10) (0.10) 
Complex technology 0.73** 0.34* 0.69*** 0.54 0.30 0.68*** 
 (0.32) (0.20) (0.19) (0.35) (0.22) (0.22) 
Pending pat. / pat.  -0.29** 0.05 0.01 -0.29** 0.06 0.01 
stock (0.13) (0.11) (0.10) (0.13) (0.11) (0.10) 
Ln(EMPL) 0.28*** 0.33*** 0.26*** 0.26*** 0.33*** 0.26*** 
 (0.03) (0.02) (0.02) (0.03) (0.03) (0.02) 
Newly founded    0.10 -0.08 -0.07 
    -0.11 (0.11) (0.10) 
East    -0.11 0.09 0.10 
    (0.14) (0.10) (0.09) 
Cost    0.07 0.03 0.13 
    (0.11) (0.09) (0.08) 
Risk    0.30** 0.19** 0.29*** 
    (0.12) (0.09) (0.09) 
Incoming spillovers    -0.43 0.31 0.17 
    (1.36) (1.04) (0.99) 
Strategic     -0.14 1.25 0.48 
appropriability    (1.50) (1.07) (1.03) 
Legal appropriability    1.85* 0.18 -0.57 
    (1.01) (0.74) (0.72) 
Ln(HHI)    0.05 0.04 0.02 
    (0.04) (0.03) (0.03) 
1992 -0.14 0.24*** 0.15** -0.28* 0.13 -0.04 
 (0.09) (0.07) (0.06) (0.15) (0.12) (0.11) 
Intercept -3.29*** -3.16*** -2.71*** -3.90*** -4.49*** -3.09*** 
 (0.36) (0.23) (0.22) (1.10) (0.78) (0.74) 
Industry dummies YES YES YES YES YES YES 
RHO21 0.66*** 0.66*** 
 (0.04) (0.04) 
RHO31 0.63*** 0.62*** 
 (0.04) (0.04) 
RHO32 0.84*** 0.84*** 
 (0.02) (0.02) 
N 2794 2794 
Log-Likelihood -2185.36 -2160.06 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Appendix 3: Probit Models Taking Forward Citations into Account 
Table 7: Probit models on the likelihood to collaborate with any type of partner 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 3.83*** 3.56*** 10.02** 9.21** 
 (0.70) (0.70) (3.97) (4.41) 
Patent stock / EMPL 2.66 2.58 1.62 1.61 
 (2.04) (2.07) (2.21) (2.27) 
Citations/ patents 0.14* 0.14* 0.02 0.03 
 (0.07) (0.08) (0.11) (0.12) 
No patent dummy 0.01 -0.01 -0.06 -0.05 
 (0.13) (0.14) (0.14) (0.14) 
No citation dummy 0.07 0.06 0.01 0.02 
 (0.13) (0.13) (0.14) (0.14) 
Complex technology 0.58*** 0.52** 0.44** 0.40* 
 (0.18) (0.21) (0.20) (0.22) 
Pending pat./ pat. stock 0.09 0.09 0.03 0.04 
 (0.10) (0.10) (0.11) (0.11) 
ln(EMPL) 0.33*** 0.34*** 0.31*** 0.32*** 
 (0.02) (0.02) (0.03) (0.03) 
Newly founded  -0.04  -0.04 
  (0.10)  (0.10) 
ln(HHI)  0.02  0.02 
  (0.03)  (0.03) 
EAST  0.17*  0.08 
  (0.09)  (0.12) 
COST  0.16*  0.14* 
  (0.08)  (0.08) 
RISK  0.23***  0.20** 
  (0.08)  (0.09) 
Incoming spillovers  0.01  -0.11 
  (0.99)  (0.97) 
Strategic appropriability  0.44  0.20 
  (1.05)  (1.03) 
Legal appropriability  0.40  0.38 
  (0.71)  (0.69) 
Y1992 0.23*** 0.06 0.18** 0.05 
 (0.06) (0.11) (0.07) (0.11) 
Intercept -2.96*** -3.67*** -2.75*** -3.22*** 
 (0.25) (0.80) (0.32) (0.91) 
Industry dummies Χ2 = 40.52*** Χ2 = 03.16*** Χ2 = 29.07*** Χ2 = 22.65*** 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Table 8: Probit models on collaboration with competitors 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 2.19*** 2.23*** 12.04*** 11.44** 
 (0.63) (0.64) (4.04) (4.53) 
Patent stock / EMPL -0.92 -1.17 -2.34 -2.49 
 (3.51) (3.64) (3.29) (3.46) 
Citations/ patents 0.16*** 0.16** -0.03 -0.02 
 (0.06) (0.07) (0.11) (0.12) 
No patent dummy -0.31* -0.28* -0.39*** -0.31** 
 (0.16) (0.16) (0.15) (0.16) 
No citation dummy 0.06 0.08 -0.04 -0.01 
 (0.16) (0.16) (0.15) (0.16) 
Complex technology 0.81** 0.69* 0.53 0.47 
 (0.33) (0.35) (0.33) (0.35) 
Pending pat./ pat. stock -0.30** -0.29** -0.36*** -0.34*** 
 (0.13) (0.13) (0.12) (0.12) 
ln(EMPL) 0.25*** 0.24*** 0.22*** 0.21*** 
 (0.03) (0.03) (0.04) (0.04) 
Newly founded  0.15  0.14 
  (0.15)  (0.14) 
ln(HHI)  0.06  0.06 
  (0.04)  (0.04) 
EAST  -0.15  -0.27* 
  (0.15)  (0.14) 
COST  0.05  0.03 
  (0.12)  (0.11) 
RISK  0.25*  0.18 
  (0.13)  (0.13) 
Incoming spillovers  -0.19  -0.50 
  (1.38)  (1.25) 
Strategic appropriability  0.61  0.21 
  (1.64)  (1.51) 
Legal appropriability  1.05  0.85 
  (0.94)  (0.88) 
Y1992 -0.15* -0.30* -0.20*** -0.28* 
 (0.08) (0.15) (0.08) (0.14) 
Intercept -3.26*** -4.26*** -2.74*** -3.22** 
 (0.39) (1.28) (0.51) (1.36) 
Industry dummies 
Χ2 = 
36.22*** 
Χ2 = 
20.74*** Χ2 = 13.41 Χ2 = 10.67 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Table 9: Probit models on collaboration with universities 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 3.80*** 3.69*** 8.36* 7.29 
 (0.66) (0.67) (4.61) (4.99) 
Patent stock / EMPL 5.02** 4.96** 4.23* 4.34* 
 (2.13) (2.15) (2.36) (2.39) 
Citations/ patents 0.02 0.03 -0.06 -0.04 
 (0.08) (0.08) (0.12) (0.12) 
No patent dummy -0.12 -0.11 -0.16 -0.13 
 (0.14) (0.14) (0.15) (0.14) 
No citation dummy -0.02 -0.01 -0.06 -0.04 
 (0.14) (0.14) (0.14) (0.14) 
Complex technology 0.40* 0.35 0.30 0.29 
 (0.20) (0.23) (0.23) (0.26) 
Pending pat. / pat. stock 0.07 0.07 0.02 0.04 
 (0.11) (0.11) (0.11) (0.11) 
ln(EMPL) 0.34*** 0.33*** 0.33*** 0.32*** 
 (0.02) (0.03) (0.03) (0.03) 
Newly founded  -0.06  -0.05 
  (0.11)  (0.11) 
ln(HHI)  0.04  0.04 
  (0.03)  (0.03) 
EAST  0.06  0.00 
  (0.10)  (0.13) 
COST  0.03  0.03 
  (0.09)  (0.09) 
RISK  0.16*  0.14 
  (0.09)  (0.10) 
Incoming spillovers  0.31  0.20 
  (1.12)  (1.11) 
Strategic appropriability  1.41  1.25 
  (1.17)  (1.19) 
Legal appropriability  0.19  0.17 
  (0.79)  (0.78) 
1992 0.21*** 0.11 0.18** 0.11 
 (0.07) (0.12) (0.08) (0.12) 
Intercept -3.17*** -4.60*** -3.04*** -4.31*** 
 (0.28) (0.92) (0.34) (1.02) 
Industry dummies 
Χ2 = 
43.80*** 
Χ2 = 
37.41*** 
Χ2 = 
29.35*** 
Χ2 = 
28.30*** 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
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Table 10: Probit models on vertical collaboration (customers and suppliers) 
 
Probit 
 
IV Probit  
(R&D instrumented) 
 Coeff. Coeff. Coeff. Coeff. 
 (Std. err.) (Std. err.) (Std. err.) (Std. err.) 
R&D intensity 2.66*** 2.49*** 0.14 -0.84 
 (0.64) (0.65) (4.87) (5.18) 
Patent Stock / EMPL 3.20 3.24 3.55 3.71* 
 (2.15) (2.19) (2.21) (2.24) 
Citations/ patents 0.08 0.08 0.12 0.13 
 (0.05) (0.05) (0.10) (0.10) 
No patent dummy -0.12 -0.11 -0.09 -0.09 
 (0.13) (0.13) (0.14) (0.13) 
No citation dummy -0.03 -0.02 -0.01 0.00 
 (0.12) (0.13) (0.13) (0.13) 
Complex technology 0.68*** 0.68*** 0.72*** 0.72*** 
 (0.19) (0.21) (0.20) (0.22) 
Pending pat. / pat. stock 0.01 0.01 0.03 0.04 
 (0.10) (0.10) (0.11) (0.11) 
ln(EMPL) 0.26*** 0.26*** 0.26*** 0.26*** 
 (0.02) (0.02) (0.02) (0.02) 
Newly founded  -0.04  -0.05 
  (0.11)  (0.11) 
ln(HHI)  0.02  0.01 
  (0.03)  (0.03) 
EAST  0.08  0.13 
  (0.10)  (0.12) 
COST  0.14  0.14* 
  (0.08)  (0.08) 
RISK  0.27***  0.29*** 
  (0.09)  (0.09) 
Incoming spillovers  0.41  0.49 
  (1.05)  (1.05) 
Strategic appropriability  0.72  0.83 
  (1.12)  (1.13) 
Legal appropriability  -0.75  -0.73 
  (0.75)  (0.74) 
Y1992 0.14** -0.08 0.16** -0.07 
 (0.06) (0.12) (0.07) (0.12) 
Intercept -2.73*** -3.32*** -2.75*** -3.48*** 
 (0.26) (0.86) (0.26) (0.88) 
Industry dummies Χ2 = 32.66*** Χ2 = 30.07*** Χ2 = 33.38*** Χ2 = 31.85*** 
N 2794 
*** (**, *) indicate a significance level of 1% (5%, 10%). 
 
